



625 State Street
Schenectady, NY 12305-2111
mvphealthcare.com

July 14, 2021

State of Vermont
Department of Financial Regulation
Attn: Sebastian Arduengo
89 Main Street
Montpelier, VT 05260-3103

RE: VT Rule H-2009-03 filing

Dear Mr. Arduengo:

I, Karla Austen, attest to the Commissioner of the Department of Financial Regulation, that MVP Health Plan, Inc. is in compliance with Part 5 of Rule H-2009-03 with no exceptions.

Sincerely,

Karla Austen
Chief Financial Officer and Executive Vice President,
Network Management
MVP Health Pan, Inc.



625 State Street
Schenectady, NY 12305-2111
mvphealthcare.com

July 12, 2021

Network Adequacy Reporting

Section 6.3

MVP has assessed its provider network according to the regulations stipulated in the State of Vermont's Rule H. For 92% of the required services, MVP is maintaining a network adequacy rate of 99% or higher. In areas where MVP falls below the regulatory standard, it is due to membership in rural counties where the provider type simply does not exist or is outside of the time/distance standards because of geography. MVP does recruit providers upon member request, even in areas where state requirements are already being met with the existing network, and consistently accepts new providers into the network. MVP is working on recruiting additional Intensive Outpatient Programs as we become aware of them. In addition, in 2020 MVP expanded their policies to allow providers to perform telehealth which will allow members to access services via telehealth if they are in an underserved area. This is very beneficial with the members obtaining access to Behavior Health Providers.

SCORE SUMMARY OVERALL RESULTS

Organization: MVP Health Plan, Inc.
License: 90309

i A manual browser refresh may be required to view updated scores

Results and Scores Selector

Results and Scores Selector Overall Results and Summary of Scores ▾

VIEW SCORING SUMMARY FOR

Evaluation product First Survey ▾

Units of Assessment Exchange HMO ▾

STANDARDS SCORE: **44.02**

[VIEW must-pass results](#)

[VIEW cap element results](#)

HEDIS + CAHPS SCORE: (/Submissions/PerformanceMeasuresReport/bf718643-afea-e911-825a-12cb866b69c2?epName=First%20Survey&uaName=Exchange%20HMO)

NA

TOTAL SCORE: **44.02**

POSSIBLE: **50.00**

i Warning: Must Pass >= 3 may be subject to denial by ROC

CATEGORY/STANDARD ROLLUP SCORES ▾

CATEGORY	STANDARD	TITLE	SELF-ASSESSED SCORE	CURRENT SCORE	ISSUES NOT MET	RECEIVED POINTS	POSSIBLE PO
		<input type="text"/>	Filter ▾	Filter ▾	Filter ▾	<input type="text"/>	<input type="text"/>
QI	QI1	Program Structure	100.00 %	100.00 %		0.90	0.90
QI	QI2	Program Operations	80.25 %	100.00 %		0.84	0.84
QI	QI3	Health Services Contracting	100.00 %	100.00 %		0.93	0.93
QI	QI4	Member Experience	45.93 %	50.00 %	✓	1.79	3.59
QI	QI5	Continuity and Coordination of Medical Care	100.00 %	100.00 %		2.38	2.38
QI	QI6	Continuity and Coordination Between Medical Care and Behavioral Healthcare	50.00 %	47.02 %	✓	0.84	1.78
QI	QI7	Delegation of QI	NA	NA		NA	0.00
					Category Score	7.71	10.45

CATEGORY	STANDARD	TITLE	SELF-ASSESSED SCORE	CURRENT SCORE	ISSUES NOT MET	RECEIVED POINTS	POSSIBLE PO
		<input type="text"/>	Filter ▾	Filter ▾	Filter ▾	<input type="text"/>	<input type="text"/>
PHM	PHM1	PHM Strategy	100.00 %	100.00 %		1.08	1.08
PHM	PHM2	Population Identification	100.00 %	82.27 %	✓	1.51	1.84
PHM	PHM3	Delivery System Supports	100.00 %	50.00 %	✓	0.41	0.83
PHM	PHM4	Wellness and Prevention	26.25 %	100.00 %		1.67	1.67
PHM	PHM5	Complex Case Management	82.73 %	85.82 %		1.43	1.67
PHM	PHM6	Population Health Management Impact	100.00 %	100.00 %		1.25	1.25
PHM	PHM7	Delegation of PHM	NA	NA		NA	0.00
					Category Score	7.38	8.36

CATEGORY	STANDARD	TITLE	SELF-ASSESSED SCORE	CURRENT SCORE	ISSUES NOT MET	RECEIVED POINTS	POSSIBLE PO
		<input type="text"/>	Filter ▾	Filter ▾	Filter ▾	<input type="text"/>	<input type="text"/>
NET	NET1	Availability of Practitioners	100.00 %	95.00 %	✓	1.61	1.70
NET	NET2	Accessibility of Services	100.00 %	70.18 %	✓	1.13	1.61
NET	NET3	Assessment of Network Adequacy	NA	NA		NA	0.00
NET	NET4	Marketplace Network Transparency and Experience	29.91 %	52.00 %	✓	0.57	1.10
NET	NET5	Continued Access to Care	100.00 %	75.31 %	✓	0.57	0.76
NET	NET6	Physician and Hospital Directories	83.95 %	76.47 %	✓	1.17	1.53
NET	NET7	Delegation of NET	92.73 %	81.82 %	✓	0.77	0.94
					Category Score	5.85	7.67

CATEGORY	STANDARD	TITLE	SELF-ASSESSED SCORE	CURRENT SCORE	ISSUES NOT MET	RECEIVED POINTS	POSSIBLE PO
		<input type="text"/>	Filter ▾	Filter ▾	Filter ▾	<input type="text"/>	<input type="text"/>
UM	UM1	Program Structure	100.00 %	100.00 %		0.47	0.47
UM	UM2	Clinical Criteria for UM Decisions	100.00 %	100.00 %		0.94	0.94
UM	UM3	Communication Services	100.00 %	100.00 %		0.28	0.28
UM	UM4	Appropriate Professionals	100.00 %	100.00 %		1.04	1.04
UM	UM5	Timeliness of UM Decisions	15.85 %	96.79 %	✓	1.37	1.41
UM	UM6	Clinical Information	NA	100.00 %		0.56	0.56
UM	UM7	Denial Notices	NA	100.00 %		1.13	1.13
UM	UM8	Policies for Appeals	100.00 %	100.00 %		0.56	0.56
UM	UM9	Appropriate Handling of Appeals	NA	100.00 %		1.41	1.41
UM	UM10	Evaluation of New Technology	100.00 %	100.00 %		0.47	0.47
UM	UM11	Procedures for Pharmaceutical Management	100.00 %	100.00 %		1.13	1.13
UM	UM12	Delegation of UM	100.00 %	100.00 %		1.05	1.05
					Category Score	10.46	10.50

CATEGORY	STANDARD	TITLE	SELF-ASSESSED SCORE	CURRENT SCORE	ISSUES NOT MET	RECEIVED POINTS	POSSIBLE PO
		<input type="text"/>	Filter ▾	Filter ▾	Filter ▾	<input type="text"/>	<input type="text"/>
CR	CR1	Credentialing Policies	100.00 %	100.00 %		0.42	0.42
CR	CR2	Credentialing Committee	100.00 %	100.00 %		0.33	0.33
CR	CR3	Credentialing Verification	NA	100.00 %		1.93	1.93
CR	CR5	Ongoing Monitoring and Interventions	100.00 %	100.00 %		0.82	0.82
CR	CR6	Notification to Authorities and Practitioner Appeal Rights	100.00 %	100.00 %		0.28	0.28
CR	CR7	Assessment of Organizational Providers	100.00 %	100.00 %		0.73	0.73
CR	CR8	Delegation of CR	100.00 %	100.00 %		0.50	0.50
					Category Score	5.04	5.04

CATEGORY	STANDARD	TITLE	SELF-ASSESSED SCORE	CURRENT SCORE	ISSUES NOT MET	RECEIVED POINTS	POSSIBLE PO
		<input type="text"/>	Filter ▾	Filter ▾	Filter ▾	<input type="text"/>	<input type="text"/>
RR	RR1	Statement of Members' Rights and Responsibilities	100.00 %	100.00 %		0.88	0.88
RR	RR2	Policies and Procedures for Complaints and Appeals	100.00 %	100.00 %		1.77	1.77
RR	RR3	Subscriber Information	100.00 %	86.08 %	✓	1.12	1.30
RR	RR4	Marketing Information	100.00 %	84.43 %	✓	1.07	1.27
RR	RR5	Delegation of RR	NA	NA		NA	0.00
					Category Score	4.86	5.25

CATEGORY	STANDARD	TITLE	SELF-ASSESSED SCORE	CURRENT SCORE	ISSUES NOT MET	RECEIVED POINTS	POSSIBLE PO
		<input type="text"/>	Filter ▾	Filter ▾	Filter ▾	<input type="text"/>	<input type="text"/>
MEM	MEM1	Functionality of Claims Processing	100.00 %	100.00 %		0.62	0.62
MEM	MEM2	Pharmacy Benefit Information	100.00 %	100.00 %		0.96	0.96
MEM	MEM3	Personalized Information on Health Plan Services	100.00 %	100.00 %		0.77	0.77
MEM	MEM4	Member Support	Incomplete	NA		NA	0.00
MEM	MEM5	Delegation of MEM	100.00 %	100.00 %		0.33	0.33
					Category Score	2.69	2.69



National Committee for Quality Assurance has awarded

MVP Health Plan, Inc.

Exchange HMO

an accreditation status of

Accredited

for service and clinical quality that meet or exceed NCQA's rigorous requirements for consumer protection and quality improvement.



David Choi, MD
CHAIR, BOARD OF DIRECTORS

Margaret S. J...
PRESIDENT

[Signature]
CHAIR, REVIEW OVERSIGHT COMMITTEE

03/02/2020
DATE GRANTED

03/02/2023
EXPIRATION DATE

ACROMEGALY

BYNFEZIA PEN

MYCAPSSA

OCTREOTIDE

SANDOSTATIN

SOMATULINE

SOMAVERT

ALPHA-1 ANTITRYPSIN DEFICIENCY

ARALAST NP

GLASSIA

PROLASTIN-C

ZEMAIRA

AMYLOIDOSIS

ONPATTRO

VYNDAMAX

VYNDAQEL

ASTHMA

CINQAIR

DUPIXENT_ASTHMA

FASENRA

NUCALA

XOLAIR

ATOPIC DERMATITIS

DUPIXENT

COAGULATION DISORDERS

CEPROTIN

CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES

ARCALYST

ILARIS

CYSTIC FIBROSIS

BETHKIS

BRONCHITOL

CAYSTON
KITABIS PAK
PULMOZYME
TOBI
TOBI PODHALER
TOBRAMYCIN

ENZYME DEFICIENCY DISORDERS – OTHER
NITISINONE

GASTROINTESTINAL DISORDERS-OTHER
GATTEX
OCALIVA
SOLESTA

GOUT
KRYSTEXXA

GROWTH HORMONE AND RELATED DISORDERS
GENOTROPIN
HUMATROPE
INCRELEX
NORDITROPIN
NUTROPIN
OMNITROPE
SAIZEN
SEROSTIM
ZOMACTON
ZORBTIVE

HEMATOPOIETICS
MOZOBIL

HEMOPHILIA, VON WILLEBRAND DISEASE & RELATED BLEEDING DISORDERS
ADVATE
ADYNOVATE
AFSTYLA
ALPHANATE
ALPHANINE SD
ALPROLIX

BEBULIN
BENEFIX
COAGADEX
CORIFACT
ELOCTATE
ESPEROCT
FEIBA
FIBRYGA
HELIXATE
HEMLIBRA
HEMOPIL M
HUMATE-P
IDELVION
IXINITY
JIVI
KOATE
KOGENATE
KOVALTRY
MONOCLATE
MONONINE
NOVOEIGHT
NOVOSEVEN RT
NUWIQ
OBIZUR
PROFILNINE SD
REBINYN
RECOMBINATE
RIASTAP
RIXUBIS
SEVENFACT
STIMATE
TRETEN
VONVENDI
WILATE
XYNTHA

HEPATITIS B

ADEFOVIR DIPIVOXIL
BARACLUDE
ENTECAVIR
EPIVIR HBV
HEPSERA
LAMIVUDINE_HEPB
VEMLIDY

HEPATITIS C

DAKLINZA
EPCLUSA
HARVONI
LEDIPASVIR/SOFOSBUVIR
MAVYRET
MODERIBA
PEGASYS
PEG-INTRON
REBETOL
RIBAPAK
RIBASPHERE
RIBAVIRIN
SOFOSBUVIR/VELPATASVIR
SOVALDI
TECHNIVIE
VIEKIRA PAK
VOSEVI
ZEPATIER

HEREDITARY ANGIOEDEMA

BERINERT
CINRYZE
FIRAZYR
HAEGARDA
ICATIBANT ACETATE
KALBITOR
RUCONEST
TAKHZYRO

HORMONAL THERAPIES

AVEED
ELIGARD
FENSOLVI
FIRMAGON
LEUPROLIDE ACETATE
LUPANETA PACK
LUPRON DEPOT
NATPARA
SUPPRELIN
TRELSTAR
VANTAS
ZOLADEX

IMMUNE DEFICIENCIES AND RELATED DISORDERS

ASCENIV
BIVIGAM
CARIMUNE
CUTAQUIG
CUVITRU
CYTOGAM
FLEBOGAMMA
GAMASTAN S/D
GAMMAGARD
GAMMAGARD LIQUID
GAMMAKED
GAMMAPLEX
GAMUNEX
HEPAGAM B
HIZENTRA
HYPERHEP B
HYPERRHO S/D
HYQVIA
MICRHOGAM
NABI-HB
OCTAGAM
PANZYGA
PRIVIGEN
RHOGAM
RHOPHYLAC
VARIZIG
WINRHO
XEMBIFY

INFECTIOUS DISEASE – OTHER

ACTIMMUNE
ALFERON N

INFERTILITY

BRAVELLE
CETROTIDE
CHORIONIC GONADOTROPIN
FOLLISTIM AQ
GANIRELIX ACETATE
GONAL-F

MENOPUR
NOVAREL
OVIDREL
PREGNYL

INFLAMMATORY BOWEL DISEASE

AVSOLA
CIMZIA
ENTYVIO
HUMIRA
INFLECTRA
REMICADE
RENFLEXIS
STELARA

IRON OVERLOAD

DEFERASIROX
DEFEROXAMINE
DESFERAL
EXJADE
JADENU

LYSOSOMAL STORAGE DISORDER

ALDURAZYME
CERDELGA
CEREZYME
CYSTAGON
ELAPRASE
ELELYSO
FABRAZYME
KANUMA
LUMIZYME
MIGLUSTAT
NAGLAZYME
VIMIZIM
VPRIV

MENTAL HEALTH CONDITIONS

ZULRESSO

MOVEMENT DISORDERS

APOKYN
AUSTEDO
DROXIDOPA
DUOPA
INBRIJA
KYNMOBI
NORTHERA
NUPLAZID
RADICAVA
TETRABENAZINE
XENAZINE

MULTIPLE SCLEROSIS

AMPYRA
AUBAGIO
AVONEX
BAFIERTAM
BETASERON
COPAXONE 20
COPAXONE 40
DALFAMPRIDINE
DIMETHYL FUMARATE
EXTAVIA
GILENYA
GLATIRAMER ACETATE 20
GLATIRAMER ACETATE 40
GLATOPA 20
GLATOPA 40
KESIMPTA
LEMTRADA
MAVENCLAD
MAYZENT
MITOXANTRONE
OCREVUS
PLEGRIDY
PONVORY
REBIF
TECFIDERA
TYSABRI
VUMERITY
ZEPOSIA

OCULAR DISORDERS

BEOVU
EYLEA
ILUVIEN
LUCENTIS
MACUGEN
OZURDEX
RETISERT
TEPEZZA
VISUDYNE

ONCOLOGY – INJECTABLE

ADCETRIS
ARZERRA
ASPARLAS
AVASTIN
AZACITIDINE
BAVENCIO
BELEODAQ
BELRAPZO
BENDAMUSTINE HYDROCHLORID
BENDEKA
BESPONSA
BLINCYTO
BORTEZOMIB
CYRAMZA
DACOGEN
DARZALEX
DECITABINE
EMPLICITI
ENHERTU
ERBITUX
ERWINAZE
EVOMELA
FOLOTYN
FUSILEV
GAZYVA
HALAVEN
HERCEPTIN
HERCEPTIN HYLECTA
HERZUMA
IMFINZI
INTRON A
ISTODAX

IXEMPRA
JEMPERLI
JEVTANA
KADCYLA
KANJINTI
KEYTRUDA
KHAPZORY
KYPROLIS
LEVOLEUCOVORIN CALCIUM
LUMOXITI
MVASI
MYLOTARG
OGIVRI
ONCASPAR
ONTRUZANT
OPDIVO
PADCEV
PERJETA
PHESGO
POLIVY
PORTRAZZA
POTELIGEO
PROLEUKIN
RIABNI
RITUXAN
RITUXAN HYCELA
ROMIDEPSIN
RUXIENCE
RYBREVANT
SARCLISA
SYLVANT
SYNRIBO
TECENTRIQ
TEMODAR (INJECTABLE)
TEMSIROLIMUS
TEPADINA
THYROGEN
TORISEL
TRAZIMERA
TREANDA
TRUXIMA
VALRUBICIN
VALSTAR
VECTIBIX
VELCADE
VIDAZA

VYXEOS
XGEVA
YERVOY
YONDELIS
ZALTRAP
ZEPZELCA
ZIRABEV
ZOLEDRONIC ACID

OSTEOPOROSIS

EVENITY
FORTEO
PROLIA
RECLAST
TERIPARATIDE
TYMLOS
ZOLEDRONIC ACID_OST

PAROXYSMAL NOCTURNAL HEMOGLOBINURIA

SOLIRIS
ULTOMIRIS

PHENYLKETONURIA

KUVAN
PALYNZIQ
SAPROPTERIN DIHYDROCHLORIDE

PRE-TERM BIRTH

HYDROXYPROGESTERONE CAPRO
MAKENA

PSORIASIS

COSENTYX
ILUMYA
OTEZLA
SILIQ
SKYRIZI
TALTZ
TREMIFYA

PULMONARY ARTERIAL HYPERTENSION

ADCIRCA
ADEMPAS
ALYQ
AMBRISENTAN
BOSENTAN
EPOPROSTENOL
FLOLAN
LETAIRIS
OPSUMIT
ORENITRAM
REMODULIN
REVATIO
SILDENAFIL CITRATE
TADALAFIL
TRACLEER
TREPROSTINIL SODIUM
TYVASO
UPTRAVI
VELETRI
VENTAVIS

PULMONARY DISORDERS – OTHER

ESBRIET
OFEV

RARE DISORDERS – OTHER

CRYSVITA
DOJOLVI
ENSPRYNG
GAMIFANT

RENAL DISEASE

CINACALCET HCL
JYNARQUE
PARSABIV
SENSIPAR

RESPIRATORY SYNCYTIAL VIRUS

SYNAGIS
RHEUMATOID ARTHRITIS

ACTEMRA
ENBREL
KEVZARA
OLUMIANT
ORENCIA
OTREXUP
RASUVO
RINVOQ
SIMPONI
XELJANZ

SEIZURE DISORDERS

EPIDIOLEX
HP ACTHAR GEL
SABRIL
VIGABATRIN
VIGADRONE

SICKLE CELL DISEASE

ADAKVEO
OXBRYTA

SLEEP DISORDER

WAKIX

SYSTEMIC LUPUS ERYTHEMATOSUS

BENLYSTA

THROMBOCYTOPENIA

DOPTELET
MULPLETA
NPLATE
PROMACTA

UREA CYCLE DISORDERS

BUPHENYL
RAVICTI
SODIUM PHENYLBUTYRATE

WILSON'S DISEASE

CLOVIQUE

CUPRIMINE

DEPEN TITRA

D-PENAMINE

PENICILLAMINE

SYPRINE

TRIENTINE